CommercialOctober 1, 2019
Anthem specialty pharmacy medical step therapy drug list clarification
Colony Stimulating Factor Agents ING-CC-0002
Effective for dates of service on and after May 1, 2019, the following specialty pharmacy codes from new or current criteria will be included in our existing specialty pharmacy medical step therapy review process. Zarxio® will be the preferred short-acting colony stimulating factor (CSF) agent over Neupogen®, Granix®, and Nivestym™®.
Anthem’s prior authorization clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.
Additional information regarding biosimilar drugs can be found by viewing the attached PDF reference document titled, “Biosimilar Drugs – What are they?”
The clinical criteria information is available on our website.
Clinical Criteria |
Status |
Drug |
HCPCS or CPT Code |
NDC Code |
ING-CC-0002 |
Preferred Agent |
Zarxio® |
Q5101 |
61314-0304-01 61314-0304-10 61314-0312-01 61314-0312-10 61314-0318-01 61314-0318-10 61314-0326-01 61314-0326-10 |
ING-CC-0002 |
Non-Preferred Agent |
Neupogen® |
J1442 |
55513-0530-01 55513-0530-10 55513-0546-01 55513-0546-10 55513-0924-01 55513-0924-10 55513-0924-91 55513-0209-01 55513-0209-10 55513-0209-91 |
ING-CC-0002 |
Non-Preferred Agent |
Granix® |
J1447 |
63459-0910-11 63459-0910-12 63459-0910-15 63459-0910-17 63459-0910-36 63459-0912-11 63459-0912-12 63459-0912-15 63459-0912-17 63459-0912-36 |
ING-CC-0002 |
Non-Preferred Agent |
Nivestym™ |
Q5110 |
00069-0291-10 00069-0291-01 00069-0292-01 00069-0292-10 |
ATTACHMENTS: Biosimilars What are they.docx.pdf (pdf - 0.26mb)
PUBLICATIONS: October 2019 Provider News
To view this article online:
Or scan this QR code with your phone